Ligand Pharmaceuticals LGND · NASDAQ
$295.54 -0.99% (-$2.96)
Summary
55 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 68 USD is left as net profit.
- Revenue grew by 11% a year over the last 3 years.
What to watch
- The share price is above the Bulios Fair Price.
- It earns only 3.9 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 29.9 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 10% a year over 5 years. Over the last 3 years it grew by 11% a year. For the next fiscal year analysts expect revenue to grow by 8.3%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 1.4 USD
- Research and development 14 USD
- Sales and administration 50 USD
- Taxes and other -33 USD
- Net profit 68 USD
Net profit, industry median (Biotechnology) -7.1 USD
Out of every 100 USD of revenue, 68 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 8.6 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 13
- Hold 4
- Sell 1
Today's price within the analysts' price targets
The average target of $339.43 is 15% above today's price. 72% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Royalty 33%
- Intangible Royalty Assets 27%
- Contract Revenue 14%
- Material Sales, Captisol, Core 8.1%
- Royalty, Kyprolis 7.2%
- Other 12%
By region
The company reports no revenue by region.
Royalty brings in 33% of revenue. Material Sales, Captisol, Core grew fastest, by 35% a year.
Segments in detail